Based on integrity and open communication, Medytox is building excellent capacity
and system to meet the global standard with commitment and courage.
Furthermore, we are endeavoring to reach $1 billion in sales, $10 billion in market value,
and to become one of the world's top 20 biopharmaceutical companies
Name | Medytox Inc. |
---|---|
Established | May 2nd, 2000 |
CEO | Hyunho Jung |
Main Products | Botulinum toxin product Hyaluronic acid filler product |
Domestic |
Medytox Building (Seoul) R&D Center (Gwanggyo, Osong) Medytox Plant I (Ochang) Medytox Plant II (Osong) Medytox Plant III (Osong) NUMECO (Seoul, Busan, Daejeon, Daegu, and Gwangju) |
International |
Luvantas (USA subsidiary) Medytox Taiwan (Taiwan joint venture) Medytox Hong Kong (Hong Kong joint venture) MedyCeles (Thailand joint venture) Medytox Thailand (Thailand local subsidiary) MDT International (Japan local subsidiary) |